Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | SVP Finance, CFO | May 08, 2019 | May 08, 2019 |
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Chief Financial Officer | February 17, 2021 | February 19, 2021 |
| Research Alliance Corp. IIRACB · Entity 122733 | Director | March 17, 2021 | March 17, 2021 |
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Chief Financial Officer | March 17, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date May 08, 2019 · Filed May 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.52 · Expires 2027-06-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-05-08 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: 25% of this option vested and became exercisable on January 3, 2018, with the remainder subject to vesting per an agreement with the Company. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.52 · Expires 2027-06-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-05-08 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: 25% of this option vested and became exercisable on January 3, 2018, with the remainder subject to vesting per an agreement with the Company. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.52 · Expires 2027-08-09 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-05-08 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: 25% of this option vested and became exercisable on January 3, 2018, with the remainder subject to vesting per an agreement with the Company. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.21 · Expires 2028-08-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-05-08 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: 25% of this option will vest and become exercisable on November 30, 2019, with the remainder to vest in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option vested and became exercisable on January 3, 2018, with the remainder subject to vesting per an agreement with the Company.
F2: 25% of this option vested and became exercisable on January 3, 2018, with the remainder subject to vesting per an agreement with the Company.
F3: 25% of this option vested and became exercisable on January 3, 2018, with the remainder subject to vesting per an agreement with the Company.
F4: 25% of this option will vest and become exercisable on November 30, 2019, with the remainder to vest in 12 equal quarterly installments thereafter.
Black Diamond Therapeutics, Inc.
Report date February 17, 2021 · Filed February 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.69 · Expires 2031-02-16 | Direct | 75,000 |
Reported balance
After 2021-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-17 · Grant · Acquired 75,000 · Balance 75,000 F1: 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter.
Research Alliance Corp. II
Report date March 17, 2021 · Filed March 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
Holding disclosure · report date 2021-03-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 30,000 F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Stoke Therapeutics, Inc.
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,172 |
Ending reported balance
After 2026-03-18 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-03-17 · Sale · Disposed 1,274 · Balance 13,476 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4. Row 2 · 2026-03-17 · Sale · Disposed 922 · Balance 12,554 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive. Row 3 · 2026-03-18 · Sale · Disposed 2,173 · Balance 10,381 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive. Row 4 · 2026-03-18 · Sale · Disposed 172 · Balance 10,209 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F5: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive. Row 5 · 2026-03-18 · Sale · Disposed 37 · Balance 10,172 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.
F5: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2026 Filed Mar 19, 2026 22:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 37 | $32.85 | $1,215.45 |
DisclosureSEC source: 0001774690-26-000006 · form4-03192026_100335.xml · nonDerivative · entry 5 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,172 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 22:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 172 | $31.79 | $5,467.67 |
DisclosureSEC source: 0001774690-26-000006 · form4-03192026_100335.xml · nonDerivative · entry 4 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,209 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 22:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,173 | $31.28 | $67,979.70 |
DisclosureSEC source: 0001774690-26-000006 · form4-03192026_100335.xml · nonDerivative · entry 3 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,381 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 22:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 922 | $33.38 | $30,772.12 |
DisclosureSEC source: 0001774690-26-000006 · form4-03192026_100335.xml · nonDerivative · entry 2 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,554 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 22:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,274 | $32.74 | $41,710.00 |
DisclosureSEC source: 0001774690-26-000006 · form4-03192026_100335.xml · nonDerivative · entry 1 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,476 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 14,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001774690-26-000004 · form4-03172026_090359.xml · derivative · entry 2 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,250 Underlying: Common Stock · 14,750 shares Expires 2029-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 14,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001774690-26-000004 · form4-03172026_090359.xml · nonDerivative · entry 1 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:22 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001774690-26-000002 · form4-02192026_090230.xml · derivative · entry 2 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-02-15 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. F3 · derivative.exercise_date: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:22 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $31.09 | $0.00 |
DisclosureSEC source: 0001774690-26-000002 · form4-02192026_090230.xml · derivative · entry 1 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 20, 2025 Filed Mar 20, 2025 22:17 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Units · Derivative | 59,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008713 · form4-03202025_100358.xml · derivative · entry 2 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires 2029-03-20 F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The award vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 20, 2025 Filed Mar 20, 2025 22:17 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 89,000 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001415889-25-008713 · form4-03202025_100358.xml · derivative · entry 1 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,000 Underlying: Common Stock · 89,000 shares Expires 2035-03-19 F1 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on April 15, 2025, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:14 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantStock Option (Right to Buy) · Derivative | 396,200 | $0.00 Strike: $14.13 | $0.00 |
DisclosureSEC source: 0001415889-24-013477 · form4-05172024_080515.xml · derivative · entry 1 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,200 Underlying: Common Stock · 396,200 shares Expires 2034-05-14 F1 · derivative.exercise_date: The stock option vests as to 1/4 of the total award on May 7, 2025, and as to 1/48 of the total award monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 23:47 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $28.69 | $0.00 |
DisclosureSEC source: 0000899243-21-007433 · doc4.xml · derivative · entry 1 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $10.86 | $0.00 |
DisclosureSEC source: 0000899243-21-001378 · doc4.xml · derivative · entry 3 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,171 Underlying: Common Stock · 3,000 shares Expires 2029-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on September 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 3,000 | $33.94 | $101,820.00 |
DisclosureSEC source: 0000899243-21-001378 · doc4.xml · nonDerivative · entry 2 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.53 to $34.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 3,000 | $10.86 | $32,580.00 |
DisclosureSEC source: 0000899243-21-001378 · doc4.xml · nonDerivative · entry 1 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 21:16 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $10.86 | $0.00 |
DisclosureSEC source: 0000899243-20-033341 · doc4.xml · derivative · entry 4 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,171 Underlying: Common Stock · 3,000 shares Expires 2029-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on September 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 21:16 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 1,941 | $34.05 | $66,093.77 |
DisclosureSEC source: 0000899243-20-033341 · doc4.xml · nonDerivative · entry 3 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.75 to $34.375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 21:16 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 1,059 | $33.27 | $35,233.04 |
DisclosureSEC source: 0000899243-20-033341 · doc4.xml · nonDerivative · entry 2 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,941 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.72 to $33.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 21:16 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 3,000 | $10.86 | $32,580.00 |
DisclosureSEC source: 0000899243-20-033341 · doc4.xml · nonDerivative · entry 1 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:00 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $10.86 | $0.00 |
DisclosureSEC source: 0000899243-20-030831 · doc4.xml · derivative · entry 3 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,171 Underlying: Common Stock · 3,000 shares Expires 2029-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on September 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:00 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 3,000 | $32.96 | $98,891.70 |
DisclosureSEC source: 0000899243-20-030831 · doc4.xml · nonDerivative · entry 2 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.65 to $33.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:00 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 3,000 | $10.86 | $32,580.00 |
DisclosureSEC source: 0000899243-20-030831 · doc4.xml · nonDerivative · entry 1 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 20:12 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $10.86 | $0.00 |
DisclosureSEC source: 0000899243-20-027904 · doc4.xml · derivative · entry 3 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,171 Underlying: Common Stock · 3,000 shares Expires 2029-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on September 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 20:12 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 3,000 | $33.53 | $100,575.90 |
DisclosureSEC source: 0000899243-20-027904 · doc4.xml · nonDerivative · entry 2 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.08 to $34.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 20:12 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 3,000 | $10.86 | $32,580.00 |
DisclosureSEC source: 0000899243-20-027904 · doc4.xml · nonDerivative · entry 1 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 22:09 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $10.86 | $0.00 |
DisclosureSEC source: 0000899243-20-025360 · doc4.xml · derivative · entry 3 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,171 Underlying: Common Stock · 3,000 shares Expires 2029-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on September 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 22:09 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 3,000 | $31.00 | $93,000.00 |
DisclosureSEC source: 0000899243-20-025360 · doc4.xml · nonDerivative · entry 2 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 22:09 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 3,000 | $10.86 | $32,580.00 |
DisclosureSEC source: 0000899243-20-025360 · doc4.xml · nonDerivative · entry 1 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:55 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 55,540 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-002446 · doc4.xml · derivative · entry 1 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,540 Underlying: Common Stock · 55,540 shares Expires 2030-01-29 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.